Case Report: Dupilumab as a steroid-sparing therapeutic option in refractory anti-p200 pemphigoid: real-world effectiveness in a patient with significant comorbidities - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Clinical Case Study: Efficacy of Dupilumab as a Steroid-Sparing Treatment for Refractory Anti-p200 Pemphigoid in a Patient with Multiple Comorbidities

  • By

  • Aikaterini Kyriakou

  • Christos Minas

  • Antonios Fantakis

  • Athanasia Tsaousi

  • Anastasia Tsitlakidou

  • Parthena Meltzanidou

  • Anthi-Maria Lazaridi

  • Alexandra Fleva

  • Anastasia Giannakou

  • Elisavet Lazaridou

  • Aikaterini Patsatsi

  • September 7, 2026

Share

Original Source(s)

Case Report: Dupilumab as a steroid-sparing therapeutic option in refractory anti-p200 pemphigoid: real-world effectiveness in a patient with significant comorbidities

  • by Aikaterini Kyriakou, Christos Minas, Antonios Fantakis, Athanasia Tsaousi, Anastasia Tsitlakidou, Parthena Meltzanidou, Anthi-Maria Lazaridi, Alexandra Fleva, Anastasia Giannakou, Elisavet Lazaridou, Aikaterini Patsatsi

  • September 7, 2026

Related Content

What shapes patient attitudes toward TBP skin cancer screening?

Expert consensus highlights communication, privacy, and staff interactions as priorities for a proposed patient-reported experience measure.

Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features

What happens to clinical skills when AI does the routine work?

“The need to be extra vigilant when you're reviewing something versus doing it from scratch can be a real problem.”